Business Wire

ZEDRA

19.7.2022 10:02:06 CEST | Business Wire | Press release

Share
ZEDRA Boosts Its Global Offering With the Launch Of Pensions & Incentives

ZEDRA, the fast-growing international specialist in Active Wealth, Corporate & Global Expansion, and Fund solutions, today announces that the firm is launching a new pensions-focused offering – Pensions & Incentives.

The launch follows several recent acquisitions in the UK pension services space by ZEDRA, including Inside Pensions, a leading independent occupational pension scheme governance support provider PTL, a leading independent Pension Trustee and Governance services provider, both in 2021; and most recently, Caledonian Trustees Limited, a specialist provider of professional independent trustee and secretarial services to corporate pension and funeral plans. As the new offering goes live, PTL Limited has adopted the ZEDRA brand and become ZEDRA Governance Limited.

ZEDRA launches this offering as the UK pension trustee and governance services sector is undergoing significant changes and facing challenges that will require both dedicated effort and investment from long-term owners. As the regulatory system has become increasingly complex over recent years, so has the challenge of running a pension scheme for employers and trustees alike.

The number of pension schemes requiring support is expected to continue to grow for the foreseeable future, due to significantly increased regulatory and compliance burdens, a focus on end game strategies which benefit from professional trustee knowledge and understanding, and a lack of available company or member nominated trustees. With its new Pensions & Incentives offering, ZEDRA is expanding its services to meet these needs.

By entering the pension services industry now, ZEDRA strengthens its 20 years of presence in the employee incentive solutions and pension services space, providing global clients with employee benefits, trustee services, pensions and associated administrative solutions, through a dedicated team in Guernsey. Trustee services have always been at the heart of ZEDRA – the firm was founded in 2016 following the sale by Barclays of its -UK and offshore trust business to a group of private investors, including ZEDRA’s current Executive Chairman, Bart Deconinck.

ZEDRA Pensions & Incentives Services will consist of six offices in London, Reading, Leeds, Birmingham, St Albans and Guernsey and is made up of approximately 80 specialists with plans to further expand the team with acquisitions in the near future in the UK and Europe.

Ivo Hemelraad, ZEDRA Chief Executive Officer , said: “We are delighted to further expand our service offering by boosting our presence in the UK pension space. The journey we started with the acquisition of Interben Trustees Limited in 2019 followed by Inside Pensions, PTL and more recently, Caledonian Trustees, brings us to a market leading position for outsourced pension services in the UK pension space and abroad. Our dedicated teams with unrivalled expertise allow us to offer even greater service to those who are committed to providing the highest quality pension schemes available.”

ENDS

Notes to Editors
For more information, please contact:

Greentarget
Jamie Brownlee / Tom Engleback / Eleonore Basle / Sebastian Merrett
+44 203 963 1893
zedra@greentarget.co.uk

About ZEDRA

Find out more at www.zedra.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye